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Research Centre and NIHR ARC West Midlands, UKIntroduction: The externally validated Kidney Failure Risk Equation (KFRE) for predicting risk of end-stage
renal disease (ESRD) has been developed, but its potential impact in a population on referrals for patients
with chronic kidney disease (CKD) from primary to specialty nephrology care is not known.
Methods: A cross-sectional population-based study of individuals in United Kingdom primary care
registered in The Health Improvement Network database was conducted. National Institute of Health and
Care Excellence (NICE) 2014 CKD guidelines versus the 4-variable KFRE set at a >3% risk of ESRD at 5
years were applied to patients identified with CKD stage 3-5 between January 1, 2016, and March 31, 2017.
Results: In all, 39,476 (36.6%) of 107,962 adults with CKD stage 3-5 had a urine albumin:creatinine ratio
(ACR) available and entered into the primary analysis. Of that, 7566 (19.2%) patients fulfilled NICE criteria
for referral, 2386 (31.5%) of whom had a #3% 5-year risk of ESRD. Also 8663 (21.9%) patients had a >3%
5-year risk of ESRD, 3483 (40.2%) of whom did not fulfill NICE criteria; this represents 8.8% of the primary
population. By using the KFRE threshold rather than NICE criteria for referral, 5869 patients (14.9% of the
primary analysis population) would have been reallocated between primary and specialist care. Imputa-
tional analysis was used for missing ACR measurements and showed similar results.
Conclusions: A risk-based referral approach would lead to a substantial reallocation of patients between
primary care and specialist nephrology care with only a small increase in numbers eligible, ensuring those
at higher risk of progression are identified.
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KD stage 3-5 prevalence in adults was recently
estimated as 7.3% in England.1 Individuals with
CKD are at an increased risk of morbidity and mortality
from cardiovascular disease.2–4 Progression to ESRD
requiring treatment with renal replacement therapy
(RRT) occurs in a small proportion of patients withspondence: Krishnarajah Nirantharakumar, Institute of
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International Reports (2021) -, -–-CKD, with an incidence of 120 per million population
in the United Kingdom in 2018.5 Guidelines for the
referral of patients with CKD from primary care to
specialist nephrology care are provided in the NICE
2014 CKD guideline.6 The indication for the large ma-
jority of these referrals is based on an increased risk of
progression to ESRD and the need for preparation for
management of ESRD.6 The guidance is based on expert
opinion and a key measure incorporated within the
referral criteria, the estimated glomerular filtration rate
(eGFR), does not quantitatively adjust for confounders
including age, sex, and urine ACR, all of which are1
CLINICAL RESEARCH HK Bhachu et al.: Risk-Based Referral Impact in Patients With CKDindependent variables for risk of progression to ESRD2;
however, ACR is included in the guidance as a variable
in its own right.
Many risk prediction models in kidney disease have
been developed for kidney failure, but most are limited
by their lack of external validation, poor methodology,
and ease of use.7 A recent systematic review recom-
mended the KFRE for use in predicting ESRD in the
cohort of patients with CKD 3-5.7 The 4-variable KFRE
estimates an individual’s risk of progression to ESRD at
2 years and 5 years with high precision8,9 based on age,
sex, eGFR (calculated using the CKD Epidemiology
Collaboration [CKD-EPI] equation) and urine ACR. CKD
populations globally have contributed to this model’s
extensive external validation,9 including CKD cohorts
within the United Kingdom,9,10 and it is being evalu-
ated in improvement programs in Canada.11–13 The
equation can easily be imbedded into electronic medi-
cal records where patients’ clinical and laboratory data
can be incorporated and it is also readily available
online.14 There may be scope to improve the accuracy
of the equation and studies have investigated the
addition of other variables15–20 or recalibrated to local
populations,10 and have also explored broadening its
use by validating certain populations such as renal
transplant recipients21,22 and children.23,24 Several
studies applying a risk of progression to ESRD of >3%
at 5 years for triaging referrals from primary care to
specialty care have found that it has reduced waiting
times for high-risk patients13 and number of referrals.25
Using the KFRE in clinical pathways may lead to better
access to appropriate care and system benefits.13
The objective of this study was to identify the
proportion of individuals who fulfill current NICE
guideline criteria for referral to specialist nephrology
services compared to the proportion meeting a pre-
defined KFRE risk threshold of >3% at 5 years for
progression to ESRD and to assess the proportion of
individuals who would be reclassified between primary
care and specialist services according to this threshold.METHODS
This was a cross-sectional population-based observa-
tional study. Data were extracted from The Health
Improvement Network (THIN) database, which com-
prises anonymized medical records of 3.6 million active
patients from 787 general practices.26,27 The database is
broadly representative of the UK population in terms of
demographics, disease prevalence, and mortality
rates.26
Patient data in THIN are derived from practices
using Vision electronic medical record software, which
stores information in a hierarchical system of clinical2
(Read) codes.28 The database includes information on
patient demographics, diagnoses, prescriptions, and
investigations. The baseline characteristics defined for
analysis in this study are described in the protocol
paper.29
The eGFR was calculated using the CKD-EPI equa-
tion (see Supplementary Methods S1) for all patients
aged 18 years and older who had an index serum
creatinine (sCr) reported between January 1, 2016, and
March 31, 2017, and where there was a second sCr level
>90 days before or after the index sCr level. Patients
with two eGFRs <60 ml/min per 1.73 m2 more than 90
days apart were defined as having CKD stage 3-5. This
was in accordance with the Kidney Disease Improving
Global Outcomes criteria for eGFR-based classification
of CKD.30 Proteinuria was quantified using urine ACR
(mg/mmol) measured within 12 months of the index sCr
record. Clinical (Read) codes were used to identify
comorbidities.
Patients were excluded from further analysis if they
had an eGFR $60 ml/min per 1.73 m2, were coded as
pregnant at the time of the recorded data, or were
receiving RRT (defined as receiving dialysis or with a
renal transplant). No defined clinical code is available
for patients who are following a supportive care
pathway for ESRD; therefore, patients were excluded
from further analysis if they had an eGFR #9 ml/min
per 1.73 m2, the mean eGFR at which patients with CKD
commence RRT in the United Kingdom.31
The proportion of patients fulfilling criteria for
referral to specialist nephrology care was calculated
based on the NICE 2014 CKD guidelines. These
comprised: (1) eGFR <30 ml/min per 1.73 m2; (2) urine
ACR $30 mg/mmol with hematuria; (3) urine ACR $70
mg/mmol and no diabetes; (4) a sustained decrease in
eGFR of $25% or a sustained decrease in eGFR of $15
ml/min per 1.73 m2 within 12 months. In addition, we
calculated the proportion of patients with urine ACR
>100 mg/mmol, including patients with diabetes;
although this is currently not identified as a referral
threshold for individuals with diabetes, these in-
dividuals are at particular risk of progression to ESRD.
The non–North American 4-variable KFRE9 (see
Supplementary Methods S1) required: age (years), sex,
CKD-EPI eGFR (ml/min per 1.73 m2) and urine ACR
(mg/mmol), with the predefined threshold for referral
from primary to specialty care of >3% risk at 5 years
for progression to ESRD.
Analysis
Stata 14 (College Station, Texas, USA: StataCorp, 2015)
was used for statistical analyses. The proportion of
patients meeting the current NICE criteria for referral
was compared to the proportion meeting the KFREKidney International Reports (2021) -, -–-
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years. The proportion of patients reclassified from
requiring or not requiring referral based on the applied
criteria was then calculated. The baseline characteris-
tics were described with categorical variables as n (%)
and continuous numerical data as median (interquartile
range). The primary analysis included only patients
who had an ACR recorded within 1 year of index sCr
measurement.
In a sensitivity analysis, missing urine ACR values
were imputed using the following method: firstly, ACR
measurements recorded within 5 years of the index sCr
were accepted as a proxy for recent ACR within 1 year
of sCr measurement. Using ACR measurements outside
of 1 year and up to 5 years from the index sCr may
provide some information on risk assessment by KFRE
and/or NICE criteria; however, an extended time gap
between eGFR calculated from the index sCr and ACR
quantification increases the potential for error because
of progression of the natural history of disease and
change of variables that can impact on ACR, including
use and dose changing of antiproteinuric agents and
change in cofactors for albuminuria such as blood
pressure and glycemic control. Further, missing ACR
measurements were imputed using multiple imputa-
tion. Multiple imputation was performed 10 times us-
ing chained equations with predictive mean matching
conditioned upon age, sex, body mass index category,
ethnicity, CKD stage, and relevant comorbidities and
medications (baseline diagnosis of diabetes, hyperten-
sion, coronary heart disease, heart failure, peripheral
vascular disease and cerebrovascular disease, systemic
lupus erythematosus, hematuria, and baseline pre-
scription of calcineurin inhibitors such as cyclosporine,
tacrolimus, and lithium). Individuals fulfilling the
conditions for referral to specialty care were identified
and the proportions meeting NICE criteria and/or KFRE
threshold for referral for each of the imputed dataset
were combined using Rubin’s rule. Proportions across
the groups (ACR within 1 year from sCr, ACR 1 to 5
years from sCr, and missing ACR) were then averaged
to calculate the overall proportion that would be
reclassified. Diagnostic checks were completed to
compare observed and imputed data; results are pre-
sented in Supplementary Figure S1 and Supplementary
Table S1. This study has been reported in accordance
with STROBE guidelines (see Supplementary Table S2).
Ethical Approval
The THIN data collection scheme and research per-
formed using THIN data were approved by the Na-
tional Health Service South-East Multicentre Research
Ethics Committee in 2003; under the terms of this
approval, studies must undergo independent scientificKidney International Reports (2021) -, -–-review. Approval for this analysis was obtained from
the Scientific Review Committee (for the use of THIN
data) in 2018 (Reference number: 18THIN061).
RESULTS
Between January 1, 2016, and March 31, 2017,
3,146,573 adults were available for follow-up in general
practices in the THIN database; of these, 878,569
(27.9%, 95% confidence interval [CI]: 27.9% to 28.0%)
had two sCr levels available within the study period.
Exclusions comprised 19,713 (2.2%, 95% CI: 2.2% to
2.3%) patients who were pregnant within 365 days of a
recorded sCr measurement and 1849 (0.21%, 95% CI:
0.20% to 0.22%) patients who were coded as receiving
treatment with RRT. Of the remaining patients, 108,307
(3.4% of the adults in the THIN database, 95% CI:
3.4% to 3.5%) had confirmed CKD; 345 (0.3%, 95% CI:
0.3 to 0.4%) of these patients were excluded as they
had an eGFR #9 ml/min per 1.73 m2. The final number
of patients included in the analysis was 107,962
(Figure 1).
A urine ACR within 12 months of the index sCr not
overlapping with a pregnancy period was available for
39,476 patients (36.6% of the patients in the analysis,
95% CI: 36.2% to 36.7%); these patients were included
in the primary analysis.
Demographic and Laboratory Data
Table 1 shows the overall characteristics of the cohort
grouped by the availability of ACR measurements. In
patients who had an ACR available versus those who
did not, there was a higher proportion of patients with
diabetes, 51.1% versus 18.4% (odds ratio: 4.63, 95%
CI: 4.50 to 4.76), and a lower eGFR (mean difference:
1.77 (95% CI: 1.64 to 1.90). Data on ethnicity were
available for 56.1% of the study population. Calcula-
tion of eGFR using the CKD-EPI equation was made
under the assumption that patients with missing
ethnicity were of non-black origin.32
Primary Analysis
Table 2 shows the number and proportion of patients
who fulfilled referral criteria by NICE and by KFRE risk
threshold; the proportion of patients are broadly
similar: 19.2% (95% CI: 18.8% to 19.6%) versus 21.9%
(95% CI: 21.5% to 22.4%), respectively. Some patients
had two or more indications for referral based on NICE
criteria, but referral would be predominantly based on
eGFR <30 ml/min per 1.73 m2, followed by a sustained
decline in eGFR.
Table 3 shows the numbers of patients with CKD
stage 3-5 who would have been reclassified between
primary and specialty care, in either direction, based
on the replacement of NICE criteria by the KFRE3
Figure 1. Flow chart for inclusion in the study. ACR, albumin:creatinine ratio; CKD, chronic kidney disease; CKD-EPI, Chronic Kidney Disease –
Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; RRT, renal replacement therapy; sCr, serum creatinine.
CLINICAL RESEARCH HK Bhachu et al.: Risk-Based Referral Impact in Patients With CKDthreshold (>3% ESRD risk at 5-years). For patients who
fulfilled criteria for NICE referral (n ¼ 7566), 31.5%
(2386, 95% CI: 30.5% to 32.6%) had a 5-year risk of
ESRD by KFRE of #3%, meaning 6.0% (95% CI: 5.8%
to 6.3%) of the patients in the primary analysis who met
NICE referral criteria would have been low risk by the
KFRE threshold. For patients with a KFRE of >3% (n ¼
8663), 40.2% (3483, 95% CI: 39.2% to 41.2%) did not
fulfil the current NICE CKD guideline for referral,
meaning 8.8% (95% CI: 8.5% to 9.1%) of patients in the
primary analysis who were high risk by the KFRE4
threshold did not fulfil NICE criteria. Of 11,049 (28.0%,
95% CI: 22.6% to 27.5%) patients who fulfilled NICE
and/or KFRE criteria, 5869 (53.1%, 95% CI: 52.2% to
54.0%) would have been reclassified between primary
and specialty care, in either direction. Therefore, 14.9%
(95% CI: 14.5% to 15.2%) of patients with CKD stage 3-
5 in the primary analysis would have been reclassified
between primary and specialty care if the KFRE criteria
replaced NICE criteria for referral.
For the individual NICE 2014 CKD guidelines for
referral considered in this study, the proportion with aKidney International Reports (2021) -, -–-
Table 1. Study Population Characteristicsa
Characteristic Total (N [ 107,962)
ACR Measurement Available Within 1 Year
(n [ 39,476)
ACR Measurement Unavailable Within 1 Year
(n [ 68,486)
Index eGFR (ml/min/1.73 m2), mean (SD) 45.34 (10.41) 44.22 (10.48) 45.99 (10.31)
Age (yrs), median (IQR) 79.52 (72.58-85.24) 78.59 (71.94-84.09) 79.93 (72.86-85.75)
Male 46,310 (42.89) 18,752 (47.50) 27,558 (40.24)
BMI categories
Underweight (<18.5 kg/m2) 1770 (1.64) 435 (1.10) 1335 (1.95)
Normal weight (18.5-25 kg/m2) 27,387 (25.37) 8601 (21.79) 18,786 (27.43)
Overweight (25-30 kg/m2) 39,452 (36.54) 14,602 (36.99) 24,850 (36.28)
Obese (>30 kg/m2) 35,513 (32.89) 15,077 (38.19) 20,436 (29.84)
Missing 3840 (3.56) 761 (1.93) 3079 (4.50)
Ethnicity
White 45,472 (42.12) 16,891 (42.79) 28,581(41.73)
Black 456 (0.42) 167 (0.42) 289 (0.42)
Chinese 186 (0.17) 73 (0.18) 113 (0.16)
South Asian 1145 (1.06) 524 (1.33) 621 (0.91)
Other 150 (0.14) 61 (0.15) 89 (0.13)
Missing 60,533 (56.09) 21,760 (55.12) 38,793 (56.64)
CKD stage (CKD-EPI eGFR, ml/min/1.73 m2)
3a (45-59) 62,251 (57.66) 20,842 (52.80) 41,409 (60.46)
3b (30-44) 35,312 (32.71) 14,227 (36.04) 21,085 (30.79)
4 (15-29) 9611 (8.90) 4106 (10.40) 5505 (8.04)
5 (9-14) 788 (0.73) 301 (0.76) 487 (0.71)
Comorbidities
Diabetes 32,814 (30.39) 20,187 (51.14) 12,627 (18.44)
Hypertension 77,075 (71.39) 29,846 (75.61) 47,229 (68.96)
Coronary heart disease 28,382 (26.29) 11,547 (29.25) 16,835 (24.58)
Chronic heart failure 11,946 (11.07) 4621 (11.71) 7325 (10.70)
Peripheral vascular disease 8281 (7.67) 3562 (9.02) 4719 (6.89)
Cerebrovascular disease 16,402 (15.19) 5997 (15.19) 10,405 (15.19)
Systemic lupus erythematosus 349 (0.32) 120 (0.30) 229 (0.33)
Hematuria 11,027 (10.21) 4370 (11.07) 6657 (9.72)
Renal stone/prostate disease 8191 (7.59) 3315 (8.40) 4876 (7.12)
History of acute kidney injury 4290 (3.97) 1644 (4.16) 2646 (3.86)
Medications
Calcineurin inhibitorb/lithium 1462 (1.35) 514 (1.30) 948 (1.38)
ACR (mg/mmol), median (IQR) 2.6 (1.0 to 9.2)
ACR, albumin:creatinine ratio; BMI, body mass index; CKD, chronic kidney disease; CKD-EPI, Chronic Kidney Disease – Epidemiology Collaboration; eGFR, estimated glomerular filtration
rate; IQR, interquartile range.
aValues shown are n (%) unless otherwise stated.
bCyclosporine or tacrolimus.
HK Bhachu et al.: Risk-Based Referral Impact in Patients With CKD CLINICAL RESEARCH5-year KFRE >3% are presented in Figure 2: 92.8%
(4090 of 4407, 95% CI: 92% to 93.6%) of those with
eGFR <30 ml/min per 1.73 m2, 76.1% (447 of 587, 95%
CI: 72.7% to 79.6%) of those with ACR >30 mg/mmol
and hematuria, 88.1% (570 of 647, 95% CI: 85.6% to
90.6%) of those with ACR > 70 mg/mmol and no
diabetes and 44.6% (1555 of 3486, 95% CI: 43.0 to
46.3%) of those with sustained decrease in eGFR.
Sensitivity Analysis
Urine ACR was imputed for the 68,486 (63.4%, 95% CI:
63.1% to 63.7%) of patients who had no ACR mea-
surement within 12 months of the index sCr. From this
group, 21,431 patients had a urine ACR value within 5
years from the index sCr date; this was accepted as a
proxy measurement. For the remaining 47,055 patients,Kidney International Reports (2021) -, -–-missing ACR data were replaced using multiple impu-
tation. This analysis yielded similar results to the pri-
mary analysis (Table 2): 17.0% (95% CI: 16.8% to
17.2%) of patients fulfilled NICE criteria for specialty
care referral; 9.6% (95% CI: 9.5% to 9.8%) with an
eGFR <30 ml/min per 1.73 m2, 1.1% (95% CI: 1.1% to
1.2%) with ACR >30 mg/mmol and hematuria, 1.9%
(95% CI: 1.8% to 1.9%) with an ACR >70 mg/mmol
and no diabetes, and 7.8% (95% CI: 7.6% to 7.9%)
with a decline in eGFR. Table 4 shows that for patients
who fulfilled criteria for NICE referral (n ¼ 18,369),
35.1% (6450, 95% CI: 34.4% to 35.8%) had a 5-year
risk of ESRD by KFRE of #3%, which is 6.0% (95%
CI: 5.8% to 6.1%) of the total CKD population. For
patients with a KFRE of >3% (n ¼ 19,649), 39.4%
(7730, 95% CI: 38.7% to 40.0%) did not fulfil the5
Table 2. Proportion and Number of Patients Fulfilling Referral
Criteria From Primary to Specialty Care
Criteria
ACR Available Within 1 Year of






All criteria 19.17 (18.78 – 19.56)
(7566) b




11.16 (10.85 – 11.48)
(4407)




1.49 (1.37 – 1.61)
(587)




1.64 (1.53 – 1.77)
(647)




8.83 (8.55 – 9.11)
(3486)
7.77 (7.62 – 7.94)
(8394)
KFRE
5-year risk >3% 21.94 (21.54 – 22.36)
(8663)
18.20 (17.97 – 18.43)
(19,649)
ACR, albumin:creatinine ratio; CI, confidence interval; eGFR, estimated glomerular
filtration rate; KFRE, kidney failure risk equation; NICE, National Institute of Health and
Care Excellence; sCr, serum creatinine.
aACR available within 5 years of index sCr considered, further missing ACRs imputed
using multiple imputation using chained equations.
bPatients to be referred to specialist nephrology care based on individual NICE criteria
do not add up to the total patients to be referred to specialist nephrology care based on
the combination of individual NICE criteria. This is because some patients have two or
more indications for referral based on the NICE 2014 guideline.
Table 3. Classification of Patients for Referral From Primary to
Specialty Care Based on NICE Criteria or a KFRE>3% at 5 Years —
Primary Analysis









No referral 28,427 (72.0) 3483 (8.8) 31,910 (80.8)
Referral 2386 (6.0) 5180 (13.1) 7566 (19.2)
Total n (%) 30,813 (78.1) 8663 (21.9) 39,476 (100)
KFRE, kidney failure risk equation; NICE, National Institute of Health and Care
Excellence.
CLINICAL RESEARCH HK Bhachu et al.: Risk-Based Referral Impact in Patients With CKDcurrent NICE CKD guideline for referral from primary
to specialty care, which is 7.2% (95% CI: 7.0% to
7.3%) of the total population. Of 26,099 patients who
fulfilled NICE and/or KFRE criteria, 14,180 (54.3%,
95% CI: 53.7% to 54.9%) would have been reclassified
between primary care and specialty care, in either di-
rection. Therefore, 13.1% (95% CI: 12.9% to 13.3%) of
the total population would have been reclassified be-
tween primary care and specialty care, in either di-
rection if the KFRE criteria replaced NICE criteria for
referral.
Adjustments in the Primary Analysis
Two additional analyses were performed to assess how
different criteria could be used to stratify patients at
risk of progression to ESRD. For example, adding a
criterion of ACR >100 mg/mmol as a threshold for
referral from primary to specialty care led to an abso-
lute increase of 1.0% (95% CI: 0.09% to 0.29%) in
patients eligible for referral. The NICE CKD guideline
currently indicates that patients with diabetes and
with an ACR >70 mg/mmol should be referred if there
is a possible cause other than diabetes. Second, an
analysis was performed for a 2-year risk of progression
threshold which showed that 2.5% (95% CI: 2.38% to
2.69%) of patients had a KFRE risk of progression to
ESRD of >10% at 2 years. This may be helpful within
specialist services as a threshold at which patients
move between clinics, for example, from a clinic
focused on slowing progression of CKD to one that also
prepares the patient for management of ESRD.6
DISCUSSION
This study found that using a risk-based threshold for
patients with CKD rather than the current NICE CKD
guideline criteria would lead to a major change in
referral patterns of individuals from primary to
specialist care. Both the primary and sensitivity ana-
lyses showed approximately 40% of patients with a
>3% risk of ESRD by 5 years are missed by the current
NICE referral criteria. Approximately one-third of pa-
tients who fulfill the current NICE criteria are at low
risk of ESRD (#3% at 5-years) including more than
half of those with a sustained decrease in eGFR as
defined in the NICE guidance. Therefore, some patients
at low risk of progression to ESRD are accessing limited
specialist nephrology resources, whereas others with a
higher risk of progression do not meet the NICE criteria
and are not identified as requiring referral. If KFRE
rather than NICE CKD criteria was used for referral of
patients, just under 15% of patients with CKD would
be reclassified between primary and specialty care.
A strength of this study is that it used amajor primary
care database which includes all adult patients in the
participating general practices. To our knowledge, this
is the first time that a study of this size has reported the
implication of using a risk equation on a population
basis for CKD. A recent study has modelled the impact of
the KFRE in one geographical area of the United
Kingdom.10 This confirmed high discrimination for the
KFRE for prediction of progression to ESRD by 5 years
(C-statistic 0.926, 95% CI: 0.911 to 0.942). In patients in
that catchment area, the use of the non–North American
calibrated KFRE at a >3% 5-year risk led to an increase
in the numbers fulfilling criteria for referral by 84.3%,
based on numbers of patients meeting NICE CKD criteria
(eGFR < 30 ml/min per 1.73 m2 and/or ACR $ 70 mg/
mmol). This differs from the current study where
additional NICE criteria (ACR > 30 mg/mmol with he-
maturia and sustained decrease in eGFR) were incorpo-
rated. This may have increased the number of patients

































Figure 2. Graph to show proportion of patients meeting current NICE 2014 CKD criteria for referral to nephrology care with a KFRE risk score
>3% at 5 years. ACR, albumin:creatinine ratio; CKD, Chronic kidney disease; eGFR, estimated glomerular filtration rate; KFRE, Kidney Failure Risk
Equation; NICE, National Institute of Health and Care Excellence.
Table 4. Classification of Patients for Referral From Primary to
Specialty Care Based on NICE Criteria or a KFRE>3% at 5 years —
Sensitivity Analysis
KFRE Threshold, n (% of Total Analysis)
Total, n (%)
No Referral
£3% 5-Year Risk (Low
Risk)
Referral
>3% 5-Year Risk (High
Risk)
NICE criteria
No referral 81,863 (75.8) 7730 (7.2) 89,593 (83.0)
Referral 6450 (6.0) 11,919 (11.0) 18,369 (17.0)
Total n (%) 88,313 (81.8) 19,649 (18.2) 107,962 (100)
KFRE, kidney failure risk equation; NICE, National Institute of Health and Care
Excellence.
HK Bhachu et al.: Risk-Based Referral Impact in Patients With CKD CLINICAL RESEARCHexplain the smaller increase in individuals of 11.1%
eligible for referral on a change in criteria to a KFRE
>3%. Of interest, further modelling in that study
indicated that referral criteria of a$5% risk of ESRD or
a urine ACR $70 mg/mmol increased the proportion of
patients referred who are likely to develop ESRD while
reducing the number of patients eligible for referral
compared to the numbers that had been seen in specialty
care in the geographical area studied.
This study emphasizes that the majority of patients
meeting current NICE CKD referral guidelines are based
on eGFR criteria. However, eGFR alone lacks sensitivity
for progression to ESRD.8 Most patients with eGFR <30
ml/min per 1.73 m2 met the threshold set for referral of
KFRE >3% at 5-years; however, this was not the case
for those with a sustained decline in eGFR where more
than half were identified as low risk of progression.
In this study, 3.4% of the study population met the
clinical definition of CKD stage 3-5 consistent with
established Kidney Disease Improving Global Outcomes
criteria for diagnosis using two measurements of kid-
ney function >90 days apart. Patients on RRT and who
were pregnant were not included in this calculated
value. This figure is lower than estimates of CKD
prevalence in other studies. Estimates of prevalence
vary widely depending on the methodology used and
each has its own limitations. In the United Kingdom,
the Quality Outcome Framework, a system whereby
primary care practices are financially incentivized for
implementing good quality of care, includes main-
taining a register of patients aged 18 years or older with
CKD stage 3-5. In 2019–2020, 4.1% of patients were
coded as having CKD.33 With this method there is a
reliance on accurate coding and a study has shownKidney International Reports (2021) -, -–-there to be major miscoding of patients with CKD:
72.1% of patients with biochemically confirmed CKD
appropriately coded, and 43.6% of patients coded as
CKD with no biochemical evidence of stage 3-5 CKD.34
Some studies have used a single measure for sCr or
eGFR which is likely to overestimate CKD as this will
not reflect variation over time such as recovery from
acute kidney injury. Data from a sample of nationally
representative individuals in the Health Survey for
England 2016 had CKD staging based on a single sCr
value used to calculate CKD-EPI eGFR; estimated
prevalence of stage 3-5 CKD was 7.3%.1 A further
study, The New Opportunities for Early Renal Inter-
vention by Computerised Assessment (NEOERICA)
study reported a prevalence of 8.2% and also used
single sCr values.35 Lastly, the Quality Improvement in
Chronic Kidney Disease (QICKD) study described and
compared the CKD prevalence values using different
methodologies in a study population of 930,997 pa-
tients from 129 primary care practices in England.
Crude prevalence of CKD stages 3-5 was 5.4% using7
CLINICAL RESEARCH HK Bhachu et al.: Risk-Based Referral Impact in Patients With CKDtwo laboratory readings at least 3 months apart to
report a Modification of Diet in Renal Disease eGFR.
Using the single latest eGFR value changed the preva-
lence to 6.4% and paired sCr values to calculate eGFR
by CKD-EPI formula and gave a prevalence of 4.8%.
The limitation in THIN and other primary care records
is that sCr values are derived from individuals access-
ing health care who go on to have a kidney function
test. For individuals who are well, if the kidney
function is not indicated or if patients poorly engage
with health care services, they may not necessarily
receive testing for kidney function. Some patients may
not have had a kidney function blood test in the period
under study. The lack of consistent prevalence esti-
mates in the literature may make interpretation of the
findings slightly challenging.
In the current study, the use of real-life data
confirmed a lack of ACR testing in patients with CKD
with 63.4% (68,486) missing this measurement in the
specified period. As a consequence, the prognostic in-
formation provided by ACR, including risk of adverse
outcomes such as cardiovascular disease, ESRD, and
death, would not be available for these patients.36
Furthermore, albuminuria is used to direct care for
patients with CKD, determining, for example, blood
pressure targets, choice of antihypertensive treat-
ments,6 and management with sodium glucose trans-
port protein 2 inhibitors.37 Our results are consistent
with a recent national CKD audit which identified
major shortfalls in the measurement of ACR in clinical
practice in the United Kingdom, an area that represents
a major opportunity for quality improvement.38 To
account for 21,431 (31.3%) of the missing ACR values,
urine ACR measurements outside of 1 year and up to 5
years from the index sCr were used as a proxy in our
sensitivity analysis. Although this allowed for risk
assessment by KFRE and/or NICE criteria, there may be
an increased potential for error given the prolonged
time gap between renal function measurement (eGFR)
and ACR quantification. Natural progression of disease
and other variables such as use of antiproteinuric
agents and change in blood pressure and glycemic
control may impact on ACR. Multiple imputation was
used for the remainder of patients with no urine ACR
measurements (n ¼ 47,055, 68.7%).
The appropriate risk threshold for referral from
primary to specialty nephrology care is not known, and
this is a weakness of this study. In some Canadian
provinces, a risk threshold of >3% is being used in
current clinical practice and this is being evaluated in
improvement programs.11–13 A further weakness of the
study included the exclusion of patients with an eGFR
of $60 ml/min per 1.73 m2 and abnormal urinalysis.
However, only young patients with nephrotic range8
proteinuria (ACR >300 mg/mmol) and an eGFR $60
ml/min per 1.73 m2 will have a risk of progression to
ESRD of >3% at 5 years. This is a rare finding in
clinical practice, and nephrotic syndrome with a
normal eGFR is an independent indication for referral
to specialty care. The study did not include the other
recommendations from NICE for a referral to specialty
care. These comprise patients with CKD who remain
hypertensive on four or more blood pressure agents
and patients who have rare or genetic causes of CKD.
These groups are separate from the expert opinion
progression thresholds defined by NICE or the KFRE
calculation; therefore, they have no material impact on
the modelling reported in this study.
The current NICE guideline recommends referral
when there is a likelihood of progression to ESRD.6 The
basis for these referral guideline recommendations to
specialty care is that patients who present late to spe-
cialty care have worse outcomes compared to patients
who have a timely referral. However, most studies on
the impact of late referral have focused on patients at a
very high risk of ESRD, where the late presenters have
been known to the kidney service for <3 months
before starting RRT.39 This study shows the risk of
progression to ESRD is low for the majority of patients
with CKD who meet current referral criteria. This is
consistent with the published literature in this area and
is because of the slow progression of CKD in most of
those affected, and the competing risk of death.40
Whether referral (identified by the NICE CKD
guideline or by a KFRE level of >3%) has an impact on
clinical outcomes or patient-reported outcomes is not
known. Most patients with CKD require careful and
supportive management of risk factors for early car-
diovascular disease, accurate management of which
will also lower the risk of progression of CKD.
Improving albuminuria testing to ensure that all pa-
tients can access treatment where there is a clear evi-
dence base for outcomes is also a priority. Using the
KFRE to ensure patients are supported to have an
appropriate understanding of their risk of ESRD, and to
support health care professionals in primary and spe-
cialty care in understanding the importance of accurate
integration of ACR into clinical management and
referral pathways may provide a further opportunity
to improve clinical care.
This study emphasizes for clinicians and policy-
makers the inaccuracy of the current NICE CKD
guideline for risk of progression to ESRD. Applying the
KFRE with a risk threshold for referral has scope for
carrying out clinical studies focused on assessing how
KFRE is used to communicate with patients with CKD
and defining a threshold for referral from primary to
specialty care. This may represent an opportunity toKidney International Reports (2021) -, -–-
HK Bhachu et al.: Risk-Based Referral Impact in Patients With CKD CLINICAL RESEARCHimprove quality of care with no additional cost, and to
contribute to a core aspiration of the National Health
Service long-term plan for the management of patients
in primary care, including through novel service de-
velopments such as virtual clinics. NICE is currently
revising the CKD guideline and the information pro-
vided in this paper provides further evidence for the
use of risk equations to inform this.41
CONCLUSIONS
This study shows that moving from expert opinion to a
risk-based threshold of ESRD of >3% for referral for
patients with CKD from primary to specialty care
would lead to a major redistribution of patients. This
finding has implications for patients, clinicians,
guideline groups, and resource allocation, and forms
the basis of a major opportunity for improving care for
patients with CKD.
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data for albumin:creatinine ratio within 5 years.
Table S2. Modified STROBE statement.REFERENCES
1. Hounkpatin HO, Harris S, Fraser SDS, et al. Prevalence of
chronic kidney disease in adults in England: comparison of
nationally representative cross-sectional surveys from 2003
to 2016. BMJ Open. 2020;10, e038423.
2. Nitsch D, Grams M, Sang Y, et al. Associations of estimated
glomerular filtration rate and albuminuria with mortality and
renal failure by sex: a meta-analysis. BMJ. 2013;346:f324.
3. Matsushita K, Coresh J, Sang Y, et al. Estimated glomerular
filtration rate and albuminuria for prediction of cardiovas-
cular outcomes: a collaborative meta-analysis of individual
participant data. Lancet Diabetes Endocrinol. 2015;3:514–
525.
4. Herzog CA, Asinger RW, Berger AK, et al. Cardiovascular
disease in chronic kidney disease. A clinical update from
Kidney Disease: Improving Global Outcomes (KDIGO). Kid-
ney Int. 2011;80:572–586.
5. UK Renal Registry (2020) UK Renal Registry 22nd Annual
Report— data to 31/12/2018, Bristol, UK. Accessed November
26, 2020. https://renal.org/audit-research/annual-report/22nd-
annual-report-data-31122018
6. National Clinical Guideline Centre (UK). Chronic Kidney Dis-
ease (Partial Update): Early Identification and Management of
Chronic Kidney Disease in Adults in Primary and Secondary
Care. Clinical Guidelines. London, United Kingdom: National
Institute for Health and Care Excellence (UK); 2014.9
CLINICAL RESEARCH HK Bhachu et al.: Risk-Based Referral Impact in Patients With CKD7. Ramspek CL, de Jong Y, Dekker FW, et al. Towards the best
kidney failure prediction tool: a systematic review and se-
lection aid. Nephrol Dial Transplant. 2020;35:1527–1538.
8. Tangri N, Stevens LA, Griffith J, et al. A predictive model for
progression of chronic kidney disease to kidney failure.
JAMA. 2011;305:1553–1559.
9. Tangri N, Grams ME, Levey AS, et al. Multinational assess-
ment of accuracy of equations for predicting risk of kidney
failure: a meta-analysis. JAMA. 2016;315:164–174.
10. Major RW, Shepherd D, Medcalf JF, et al. The kidney
failure risk equation for prediction of end stage renal
disease in UK primary care: an external validation and
clinical impact projection cohort study. PLoS Med.
2019;16, e1002955.
11. Hemmelgarn BR, Smekal MD, Weaver RG, et al. Imple-
mentation and evaluation of a risk-based approach to guide
chronic kidney disease care: protocol for a multiphase mixed-
methods study. Can J Kidney Health Dis. 2018;5,
2054358117753618.
12. Harasemiw O, Drummond N, Singer A, et al. Integrating risk-
based care for patients with chronic kidney disease in the
community: study protocol for a cluster randomized trial. Can
J Kidney Health Dis. 2019;6, 2054358119841611.
13. Hingwala J, Wojciechowski P, Hiebert B, et al. Risk-based
triage for nephrology referrals using the kidney failure risk
equation. Can J Kidney Health Dis. 2017;4, 2054358117722782.
14. The Kidney Failure Risk Equation. Accessed October 30, 2017.
http://kidneyfailurerisk.com/
15. Lennartz CS, Pickering JW, Seiler-Mussler S, et al. External
validation of the kidney failure risk equation and re-
calibration with addition of ultrasound parameters. Clin J
Am Soc Nephrol. 2016;11:609–615.
16. Fenton A, Jesky MD, Webster R, et al. Association between
urinary free light chains and progression to end stage renal
disease in chronic kidney disease. PLoS One. 2018;13,
e0197043.
17. SawhneyS,BeaulieuM,BlackC, et al. Predicting kidney failure risk
after acute kidney injuryamongpeople receivingnephrologyclinic
care. Nephrol Dial Transplant. 2020;35:836–845.
18. Yamanouchi M, Hoshino J, Ubara Y, et al. Value of adding the
renal pathological score to the kidney failure risk equation in
advanced diabetic nephropathy. PLoS One. 2018;13,
e0190930.
19. Zacharias HU, Altenbuchinger M, Schultheiss UT, et al.
A novel metabolic signature to predict the requirement of
dialysis or renal transplantation in patients with chronic kid-
ney disease. J Proteome Res. 2019;18:1796–1805.
20. Akbari A, Tangri N, Brown PA, et al. Prediction of progression
in polycystic kidney disease using the kidney failure risk
equation and ultrasound parameters. Can J Kidney Health
Dis. 2020;7, 2054358120911274.
21. Tangri N, Ferguson TW, Wiebe C, et al. Validation of the
kidney failure risk equation in kidney transplant recipients.
Can J Kidney Health Dis. 2020;7, 2054358120922627.
22. Akbari S, Knoll G, White CA, et al. Accuracy of kidney failure
risk equation in transplant recipients. Kidney Int Rep. 2019;4:
1334–1337.
23. Winnicki E, McCulloch CE, Mitsnefes MM, et al. Use of the
kidney failure risk equation to determine the risk of10progression to end-stage renal disease in children with
chronic kidney disease. JAMA Pediatr. 2018;172:174–180.
24. Sebastiao YV, Cooper JN, Becknell B, et al. Prediction of
kidney failure in children with chronic kidney disease and
obstructive uropathy. Pediatr Nephrol. 2021;36:111–118.
25. Hong R, Pirabhahar S, Turner K, et al. Triage system for
nephrology referrals using the kidney failure risk equation
(KFRE) score. Nephrology. 2020;25(suppl 3):53.
26. Blak BT, Thompson M, Dattani H, et al. Generalisability of The
Health Improvement Network (THIN) database: de-
mographics, chronic disease prevalence and mortality rates.
Inform Prim Care. 2011;19:251–255.
27. Maguire A, Blak BT, Thompson M. The importance of
defining periods of complete mortality reporting for research
using automated data from primary care. Pharmacoepide-
miol Drug Saf. 2009;18:76–83.
28. Booth N. What are the read codes? Health Libr Rev. 1994;11:
177–182.
29. Bhachu HK, Cockwell P, Subramanian A, et al. Cross-
sectional observation study to investigate the impact of
risk-based stratification on care pathways for patients with
chronic kidney disease: protocol paper. BMJ Open. 2019;9,
e027315.
30. Stevens PE, Levin A. Kidney Disease: Improving Global Out-
comes Chronic Kidney Disease Guideline Development Work
Group M. Evaluation and management of chronic kidney
disease: synopsis of the kidney disease: improving global
outcomes 2012 clinical practice guideline. Ann Intern Med.
2013;158:825–830.
31. Gilg J, Methven S, Casula A, et al. UK Renal Registry 19th
annual report: chapter 1 UK RRT adult incidence in 2015:
national and centre-specific analyses. Nephron.
2017;137(suppl 1):11–44.
32. Mathur R, Bhaskaran K, Chaturvedi N, et al. Completeness
and usability of ethnicity data in UK-based primary care and
hospital databases. J Public Health (Oxf). 2014;36:684–692.
33. Quality and Outcomes Framework, 2019-20. NHS Digital.




34. Jain P, Calvert M, Cockwell P, et al. The need for improved
identification and accurate classification of stages 3-5 chronic
kidney disease in primary care: retrospective cohort study.
PLoS One. 2014;9, e100831.
35. Stevens PE, O’Donoghue DJ, de Lusignan S, et al. Chronic
kidney disease management in the United Kingdom: NEO-
ERICA project results. Kidney Int. 2007;72:92–99.
36. Tangri N, Kitsios GD, Inker LA, et al. Risk prediction models
for patients with chronic kidney disease: a systematic review.
Ann Intern Med. 2013;158:596–603.
37. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal
outcomes in type 2 diabetes and nephropathy. N Engl J Med.
2019;380:2295–2306.
38. Kim LG, Cleary F, Wheeler DC, et al. How do primary care
doctors in England and Wales code and manage people with
chronic kidney disease? Results from the National Chronic
Kidney Disease Audit. Nephrol Dial Transplant. 2018;33:1373–
1379.Kidney International Reports (2021) -, -–-
HK Bhachu et al.: Risk-Based Referral Impact in Patients With CKD CLINICAL RESEARCH39. Smart NA, Dieberg G, Ladhani M, et al. Early referral to
specialist nephrology services for preventing the progression
to end-stage kidney disease. Cochrane Database Syst Rev.
2014;6:CD007333.
40. Hallan SI, Matsushita K, Sang Y, et al. Age and association of
kidney measures with mortality and end-stage renal disease.
JAMA. 2012;308:2349–2360.
41. National Institute for Health and Clinical Excellence. Surveil-
lance report 2017— chronic kidney disease (stage 4 or 5):Kidney International Reports (2021) -, -–-management of hyperphosphataemia (2013) NICE guideline
CG157, chronic kidney disease in adults: assessment and
management (2014) NICE guideline CG182 and chronic kid-
ney disease: managing anaemia (2015) NICE guideline NG8.
Accessed November 11, 2020 https://www.nice.org.uk/
guidance/cg182/resources/surveillance-report-2017-chronic-
kidney-disease-stage-4-or-5-management-of-hyper-
phosphataemia-2013-nice-guideline-cg157-chronic-kidney-
disease-in-adults-assessment-and-management-2014-nice-
guideline–4429248445/chapter/Surveillance-decision.11
